Status:

RECRUITING

Ovarian Tissue Cryopreservation in Post Pubertal (OTC-Post Pubertal)

Lead Sponsor:

Erin Rowell

Conditions:

Pediatric Cancer

Eligibility:

FEMALE

Up to 30 years

Brief Summary

The purpose of this study is to safely remove ovarian tissue in pediatric patients, who are at risk for infertility from their medical treatment, for freezing for future restoration of fertility and h...

Detailed Description

Participants are invited to take part in this study because they will be treated with chemotherapy, radiation and/or surgery that will likely affect the child's ovaries and cause the child to become i...

Eligibility Criteria

Inclusion

  • Post-pubertal individuals \< 30 years of age
  • Will undergo imminent surgery, chemotherapy or radiation therapy that has implications on future fertility and reproductive hormone potential: any health condition or malignancy that requires removal of all or part of one or both ovaries, whole abdomen or pelvic irradiation≥ 10Gy in post-pubertal girls or ≥15 Gy in pre- pubertal girls
  • total body irradiation, and
  • alkylating-intensive chemotherapy
  • cyclophosphamide cumulative dose ≥7.5 g/m2
  • any treatment regimen containing procarbazine
  • busulfan cumulative dose \>600 mg/m2
  • alkylating chemotherapy conditioning prior to stem cell transplantation
  • combination of any alkylating agent with total body irradiation or whole abdomen or pelvic radiation
  • cranial radiation ≥30 Gy
  • summed alkylating agent dose score ≥3 (Green et al., 2009)
  • cyclophosphamide equivalent dose (CED) ≥ 4,000 mg/m2 (Green et al., 2014)
  • Patients may have newly diagnosed or relapsed disease. Those who were not enrolled at diagnosis are eligible even if they have received therapy that is viewed as likely to result in complete and permanent loss of ovarian function. However, these patients will be required to provide a 4mm punch biopsy of their tissue for research.

Exclusion

  • Patients with no anticipated oncologic therapies
  • Pregnant children
  • Children with one ovary
  • Children deemed high risk for perioperative complications
  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)

Key Trial Info

Start Date :

November 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

January 1 2035

Estimated Enrollment :

250 Patients enrolled

Trial Details

Trial ID

NCT05309746

Start Date

November 1 2017

End Date

January 1 2035

Last Update

November 18 2024

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Ann &Robert H Lurie Children's Hospital

Chicago, Illinois, United States, 60611